156 related articles for article (PubMed ID: 31521062)
1. Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study.
Lisinski A; Hieronymus F; Näslund J; Nilsson S; Eriksson E
Neuropsychopharmacology; 2020 Feb; 45(3):553-560. PubMed ID: 31521062
[TBL] [Abstract][Full Text] [Related]
2. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
Hieronymus F; Lisinski A; Nilsson S; Eriksson E
Lancet Psychiatry; 2019 Sep; 6(9):745-752. PubMed ID: 31303567
[TBL] [Abstract][Full Text] [Related]
3. Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo.
Lisinski A; Hieronymus F; Nilsson S; Eriksson E
Transl Psychiatry; 2022 Apr; 12(1):160. PubMed ID: 35422023
[TBL] [Abstract][Full Text] [Related]
4. Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors.
Sheehan DV; Mancini M; Wang J; Berggren L; Cao H; Dueñas HJ; Yue L
Hum Psychopharmacol; 2016 Jan; 31(1):53-63. PubMed ID: 26331440
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
6. Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis.
Hieronymus F; Lisinski A; Eriksson E; Østergaard SD
Transl Psychiatry; 2021 Apr; 11(1):249. PubMed ID: 33907188
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine versus other anti-depressive agents for depression.
Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
[TBL] [Abstract][Full Text] [Related]
10. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression.
Hieronymus F; Emilsson JF; Nilsson S; Eriksson E
Mol Psychiatry; 2016 Apr; 21(4):523-30. PubMed ID: 25917369
[TBL] [Abstract][Full Text] [Related]
11. Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials.
Harada E; Kato M; Fujikoshi S; Wohlreich MM; Berggren L; Tokuoka H
Int J Clin Pract; 2015 Oct; 69(10):1139-48. PubMed ID: 25980552
[TBL] [Abstract][Full Text] [Related]
12. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?
Fava M; Mallinckrodt CH; Detke MJ; Watkin JG; Wohlreich MM
J Clin Psychiatry; 2004 Apr; 65(4):521-30. PubMed ID: 15119915
[TBL] [Abstract][Full Text] [Related]
13. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
14. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
15. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
[TBL] [Abstract][Full Text] [Related]
17. Impact of pretreatment with antidepressants on the efficacy of duloxetine in terms of mood symptoms and functioning: an analysis of 15 pooled major depressive disorder studies.
Barros BR; Schacht A; Happich M; Televantou F; Berggren L; Walker DJ; Dueñas HJ
Prim Care Companion CNS Disord; 2014; 16(5):. PubMed ID: 25667808
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine in treatment of anxiety symptoms associated with depression.
Dunner DL; Goldstein DJ; Mallinckrodt C; Lu Y; Detke MJ
Depress Anxiety; 2003; 18(2):53-61. PubMed ID: 12964171
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials.
Hengartner MP; Jakobsen JC; Sørensen A; Plöderl M
PLoS One; 2020; 15(2):e0229381. PubMed ID: 32101579
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
Shelton RC; Andorn AC; Mallinckrodt CH; Wohlreich MM; Raskin J; Watkin JG; Detke MJ
Int Clin Psychopharmacol; 2007 Nov; 22(6):348-55. PubMed ID: 17917553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
